Raloxifene: Difference between revisions
Jump to navigation
Jump to search
imported>Tom Morris No edit summary |
imported>Meg Taylor No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[pharmacology]], '''raloxifene''' is "a second generation [[selective estrogen receptor modulator]] (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and [[cholesterol]] metabolism but behaves as a complete [[estrogen]] antagonist on mammary gland and uterine tissue."<ref>{{MeSH}}</ref> | |||
In [[pharmacology]], '''raloxifene''' is "a second generation [[selective estrogen receptor modulator]] (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist | |||
==External links== | ==External links== | ||
| Line 7: | Line 6: | ||
==References== | ==References== | ||
{{reflist}} | |||
Latest revision as of 01:15, 7 October 2013
In pharmacology, raloxifene is "a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue."[1]
External links
The most up-to-date information about Raloxifene and other drugs can be found at the following sites.
- Raloxifene - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Raloxifene - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Raloxifene - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Raloxifene (English). Medical Subject Headings. U.S. National Library of Medicine.